NASDAQ:BEAT - BioTelemetry Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $74.50 -0.35 (-0.47 %) (As of 02/20/2019 12:20 PM ET)Previous Close$74.85Today's Range$73.30 - $74.7452-Week Range$29.85 - $80.92Volume15,052 shsAverage Volume600,131 shsMarket Capitalization$2.48 billionP/E Ratio76.03Dividend YieldN/ABeta1.75 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTelemetry, Inc., a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry service; and event monitoring services to prescribe wireless event, digital loop event, memory loop event, and non-loop event monitors. It also provides Holter and extended-wear Holter monitors, and pacemaker and international normalized ratio monitoring services to cardiologists and electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, including cardiac monitoring, imaging, scientific consulting, and data management services for drug, medical treatment, and device trials to pharmaceutical companies and contract research organizations. This segment's centralized services comprise ECG, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The Technology segment focuses on the manufacture, engineering, and development of non-invasive cardiac monitors for healthcare companies, clinics, and hospitals worldwide. This segment offers various devices that include event monitors, digital Holter monitors, and mobile cardiac telemetry monitors, as well as a wireless BGM system. BioTelemetry, Inc. is headquartered in Malvern, Pennsylvania. Receive BEAT News and Ratings via Email Sign-up to receive the latest news and ratings for BEAT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BEAT Previous Symbol CUSIPN/A Webwww.gobio.com Phone610-729-7000Debt Debt-to-Equity Ratio0.66 Current Ratio2.68 Quick Ratio2.50Price-To-Earnings Trailing P/E Ratio76.03 Forward P/E Ratio41.16 P/E Growth4.36 Sales & Book Value Annual Sales$286.78 million Price / Sales8.65 Cash Flow$1.7965 per share Price / Cash Flow41.47 Book Value$7.70 per share Price / Book9.68Profitability EPS (Most Recent Fiscal Year)$0.97 Net Income$-15,950,000.00 Net Margins4.34% Return on Equity22.56% Return on Assets11.15%Miscellaneous Employees1,600 Outstanding Shares33,300,000Market Cap$2.48 billion OptionableOptionable BioTelemetry (NASDAQ:BEAT) Frequently Asked Questions What is BioTelemetry's stock symbol? BioTelemetry trades on the NASDAQ under the ticker symbol "BEAT." How were BioTelemetry's earnings last quarter? BioTelemetry Inc (NASDAQ:BEAT) posted its quarterly earnings data on Tuesday, October, 30th. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.32 by $0.21. The medical research company had revenue of $100 million for the quarter, compared to the consensus estimate of $97.89 million. BioTelemetry had a return on equity of 22.56% and a net margin of 4.34%. The company's quarterly revenue was up 23.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.16 EPS. View BioTelemetry's Earnings History. When is BioTelemetry's next earnings date? BioTelemetry is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for BioTelemetry. How can I listen to BioTelemetry's earnings call? BioTelemetry will be holding an earnings conference call on Thursday, February 21st at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. What price target have analysts set for BEAT? 6 brokers have issued 12-month target prices for BioTelemetry's shares. Their forecasts range from $41.00 to $95.00. On average, they expect BioTelemetry's share price to reach $68.50 in the next year. This suggests that the stock has a possible downside of 8.1%. View Analyst Price Targets for BioTelemetry. What is the consensus analysts' recommendation for BioTelemetry? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTelemetry. Has BioTelemetry been receiving favorable news coverage? News coverage about BEAT stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BioTelemetry earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of BioTelemetry's key competitors? Some companies that are related to BioTelemetry include Davita (DVA), DENTSPLY SIRONA (XRAY), Henry Schein (HSIC), Sarepta Therapeutics (SRPT), Aurora Cannabis (ACB), Genmab A/S (GNMSF), WILLIAM DEMANT/ADR (WILYY), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Qiagen (QGEN), H. Lundbeck A/S- (HLUYY), Molina Healthcare (MOH), Bio-Rad Laboratories (BIO), Ionis Pharmaceuticals (IONS) and Beigene (BGNE). Who are BioTelemetry's key executives? BioTelemetry's management team includes the folowing people: Mr. Joseph H. Capper, CEO, Pres & Director (Age 55)Ms. Heather C. Getz, Exec. VP & CFO (Age 44)Mr. Peter F. Ferola, Sr. VP, Gen. Counsel & Sec. (Age 50)Mr. Fred Broadway III, Pres of BioTel Heart (Age 49)Mr. Tim Raher, Sr. VP of HR Who are BioTelemetry's major shareholders? BioTelemetry's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.29%), Dimensional Fund Advisors LP (4.00%), Macquarie Group Ltd. (2.93%), Bank of New York Mellon Corp (2.32%), Ranger Investment Management L.P. (1.45%) and Northern Trust Corp (1.40%). Company insiders that own BioTelemetry stock include Daniel Wisniewski, Fred Broadway, George Hrenko, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Institutional Ownership Trends for BioTelemetry. Which major investors are selling BioTelemetry stock? BEAT stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Falcon Point Capital LLC, Pembroke Management LTD, Millennium Management LLC, Castleark Management LLC, Summit Creek Advisors LLC, Bank of New York Mellon Corp and First Trust Advisors LP. Company insiders that have sold BioTelemetry company stock in the last year include Daniel Wisniewski, Fred Broadway, Heather C Getz, Joseph H Capper, Kirk E Gorman, Peter Ferola, Rebecca W Rimel and Robert J Rubin. View Insider Buying and Selling for BioTelemetry. Which major investors are buying BioTelemetry stock? BEAT stock was purchased by a variety of institutional investors in the last quarter, including Legal & General Group Plc, BlackRock Inc., SG Americas Securities LLC, Geode Capital Management LLC, ClariVest Asset Management LLC, Hodges Capital Management Inc., Bank of America Corp DE and Advisor Group Inc.. View Insider Buying and Selling for BioTelemetry. How do I buy shares of BioTelemetry? Shares of BEAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioTelemetry's stock price today? One share of BEAT stock can currently be purchased for approximately $74.50. How big of a company is BioTelemetry? BioTelemetry has a market capitalization of $2.48 billion and generates $286.78 million in revenue each year. The medical research company earns $-15,950,000.00 in net income (profit) each year or $0.97 on an earnings per share basis. BioTelemetry employs 1,600 workers across the globe. What is BioTelemetry's official website? The official website for BioTelemetry is http://www.gobio.com. How can I contact BioTelemetry? BioTelemetry's mailing address is 1000 Cedar Hollow Road, Malvern PA, 19355. The medical research company can be reached via phone at 610-729-7000 or via email at [email protected] MarketBeat Community Rating for BioTelemetry (NASDAQ BEAT)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 287 (Vote Outperform)Underperform Votes: 244 (Vote Underperform)Total Votes: 531MarketBeat's community ratings are surveys of what our community members think about BioTelemetry and other stocks. Vote "Outperform" if you believe BEAT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BEAT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: What is the NASDAQ Stock Market?